EMA tells countries to prioritise weight loss drugs for patients ‘with greatest need’

A European Medicines Agency steering group has asked member countries to work with marketing authorisation holders to “control and optimise the distribution” of glucagon-like peptide-1 receptor agonists.
woman injecting ozempic into stomach
There have been shortages of weight loss products, including Ozempic, since 2022

Shutterstock.com

The European Medicines Agency (EMA) has recommended that member countries develop guidelines to prioritise glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients who have the greatest need for the medicines, owing to ongoing shortages of the products.

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Last updated